Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (> 55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial) - Stelljes, Matthias; Alakel, Nael; Waesch, Ralph; Scholl, Sebastian; Nachtkamp, Kathrin; Rank, Andreas; Haenel, Mathias; Spriewald, Bernd; Hanoun, Maher; Martin, Sonja; Schwab, Katjana; Knaden, Julian; et al. (BLOOD, 2022)
CRIS-Team WoS Importer:2023-03-10